PE20221314A1 - DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION - Google Patents
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPIONInfo
- Publication number
- PE20221314A1 PE20221314A1 PE2022000441A PE2022000441A PE20221314A1 PE 20221314 A1 PE20221314 A1 PE 20221314A1 PE 2022000441 A PE2022000441 A PE 2022000441A PE 2022000441 A PE2022000441 A PE 2022000441A PE 20221314 A1 PE20221314 A1 PE 20221314A1
- Authority
- PE
- Peru
- Prior art keywords
- methods
- dosage forms
- enantiomerically enriched
- bupropion
- pure bupropion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se refiere a una forma de dosificacion para el tratamiento de una afeccion en un ser humano, la cual comprende el (S)-bupropion que es por lo menos el 95 por ciento enantiomericamente puro o un exceso enantiomerico de (S)-bupropion, en donde la forma de dosificacion se administra por la via oral una vez o dos veces al dia al ser humano.Refers to a dosage form for the treatment of a condition in a human, which comprises (S)-bupropion that is at least 95 percent enantiomerically pure or an enantiomeric excess of (S)-bupropion, in wherein the dosage form is administered orally once or twice daily to the human.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/052210 WO2020061486A2 (en) | 2018-09-20 | 2019-09-20 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US202062971174P | 2020-02-06 | 2020-02-06 | |
| US202062978626P | 2020-02-19 | 2020-02-19 | |
| US202062992060P | 2020-03-19 | 2020-03-19 | |
| US16/830,637 US20200222339A1 (en) | 2018-09-20 | 2020-03-26 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US16/907,691 US11433035B2 (en) | 2018-09-20 | 2020-06-22 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| PCT/US2020/046755 WO2021055124A1 (en) | 2019-09-20 | 2020-08-18 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221314A1 true PE20221314A1 (en) | 2022-09-07 |
Family
ID=74884634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000441A PE20221314A1 (en) | 2019-09-20 | 2020-08-18 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4031121A4 (en) |
| JP (2) | JP2022549192A (en) |
| KR (1) | KR20220066930A (en) |
| CN (1) | CN114423417A (en) |
| AU (2) | AU2020349419B2 (en) |
| BR (1) | BR112022005045A2 (en) |
| CA (1) | CA3154718A1 (en) |
| CO (1) | CO2022003126A2 (en) |
| CR (1) | CR20220119A (en) |
| EC (1) | ECSP22030119A (en) |
| IL (1) | IL291514A (en) |
| MX (1) | MX2022003346A (en) |
| NZ (1) | NZ786429A (en) |
| PE (1) | PE20221314A1 (en) |
| WO (1) | WO2021055124A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2318960A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
| US6150420A (en) * | 1998-06-01 | 2000-11-21 | Theramax, Inc. | Method for enhanced brain delivery of bupropion |
| US20190216800A1 (en) * | 2013-11-05 | 2019-07-18 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| MX2013014166A (en) * | 2013-12-03 | 2015-06-10 | Inst De Investigacion En Quimica Aplic S A De C V | Active enantiomers and the salts thereof for treating obesity. |
| US9732031B2 (en) * | 2013-12-20 | 2017-08-15 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| IL276871B2 (en) * | 2018-02-23 | 2024-11-01 | Axsome Therapeutics Inc | Pure bupropion dosage forms and methods for enantiomeric distortion purposes |
-
2020
- 2020-08-18 CN CN202080065520.4A patent/CN114423417A/en active Pending
- 2020-08-18 BR BR112022005045A patent/BR112022005045A2/en unknown
- 2020-08-18 KR KR1020227013095A patent/KR20220066930A/en not_active Ceased
- 2020-08-18 CR CR20220119A patent/CR20220119A/en unknown
- 2020-08-18 MX MX2022003346A patent/MX2022003346A/en unknown
- 2020-08-18 AU AU2020349419A patent/AU2020349419B2/en active Active
- 2020-08-18 PE PE2022000441A patent/PE20221314A1/en unknown
- 2020-08-18 WO PCT/US2020/046755 patent/WO2021055124A1/en not_active Ceased
- 2020-08-18 CA CA3154718A patent/CA3154718A1/en active Pending
- 2020-08-18 JP JP2022517743A patent/JP2022549192A/en active Pending
- 2020-08-18 EP EP20866164.5A patent/EP4031121A4/en active Pending
- 2020-08-18 NZ NZ786429A patent/NZ786429A/en active IP Right Revival
-
2022
- 2022-03-18 CO CONC2022/0003126A patent/CO2022003126A2/en unknown
- 2022-03-20 IL IL291514A patent/IL291514A/en unknown
- 2022-04-13 EC ECSENADI202230119A patent/ECSP22030119A/en unknown
-
2024
- 2024-01-05 AU AU2024200081A patent/AU2024200081B2/en active Active
- 2024-02-22 JP JP2024025971A patent/JP2024059812A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4031121A4 (en) | 2022-11-30 |
| MX2022003346A (en) | 2022-04-11 |
| CR20220119A (en) | 2022-06-22 |
| CA3154718A1 (en) | 2021-03-25 |
| EP4031121A1 (en) | 2022-07-27 |
| JP2022549192A (en) | 2022-11-24 |
| IL291514A (en) | 2022-05-01 |
| AU2020349419B2 (en) | 2023-11-02 |
| CO2022003126A2 (en) | 2022-04-19 |
| NZ786429A (en) | 2025-08-29 |
| JP2024059812A (en) | 2024-05-01 |
| KR20220066930A (en) | 2022-05-24 |
| WO2021055124A1 (en) | 2021-03-25 |
| CN114423417A (en) | 2022-04-29 |
| AU2024200081B2 (en) | 2025-11-27 |
| AU2020349419A1 (en) | 2022-03-24 |
| ECSP22030119A (en) | 2022-05-31 |
| AU2024200081A1 (en) | 2024-01-25 |
| BR112022005045A2 (en) | 2022-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001810A1 (en) | Combination of dextromethorphan and bupropion for the treatment of depression | |
| MX2021002322A (en) | Novel methods. | |
| CL2020002512A1 (en) | Treatment of hidradenitis suppurativa using jak inhibitors. | |
| CL2019003924A1 (en) | Use of pridopidine for the treatment of functional decline. (divisional application 201900485). | |
| MX394931B (en) | SPLINT FOR ORAL CARE. | |
| WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| AR048833A1 (en) | PROCEDURE FOR THE TREATMENT OF PREMENSTRUAL DISORDERS AND OTHER FEMALE SEXUAL DISORDERS | |
| MX2020006284A (en) | Bis-choline tetrathiomolybdate for treating wilson disease. | |
| CL2019002218A1 (en) | Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease. | |
| CL2020000491A1 (en) | Methods to increase and / or stabilize cardiac function in patients with Fabry disease. | |
| PE20211199A1 (en) | USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY | |
| MX2023000187A (en) | DOSAGE OF VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER. | |
| AR111374A1 (en) | USE OF LIK066 IN PATIENTS WITH HEART FAILURE | |
| EP4527456A3 (en) | Treating acromegaly with oral octreotide | |
| NO20082672L (en) | Use of cycletanine and other fluoropyridines for the treatment of systolic-dominant hypertension, isolated hypertension, increased pulse pressure and general hypertension | |
| PE20242200A1 (en) | MIRDAMETINIB TREATMENT | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| PE20221314A1 (en) | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | |
| MX2021009488A (en) | USE OF VIBEGRON TO TREAT OVERACTIVE BLADDER. | |
| MX2018015208A (en) | ANDROGRAPHOLID TO TREAT PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS. | |
| AR109760A1 (en) | COMPOSITIONS AND METHODS TO TREAT ALZHEIMER'S EVIL AND PARKINSON'S DISEASE | |
| MX2021007324A (en) | Oral therapy using 6,8-bis-benzylthio-octanoic acid. | |
| PE20210370A1 (en) | METHODS TO MODULATE PLASMA LEVELS OF TETRABENAZINE METABOLITES USING BUPROPION | |
| UA117043U (en) | METHOD OF TREATMENT OF CHRONIC PERIODONTITIS | |
| MX2022002947A (en) | Avocatin b for the treatment of diseases and conditions. |